Home › Funds › StepStone Group LP › TRDA
StepStone Group LP position in TRDA
ENTRADA THERAPEUTICS INC · Health Care
StepStone Group LP reported holding 761,277 shares of TRDA (ENTRADA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$5.6M, representing 0.26% of its reported portfolio and ranking #9 among its reported holdings. StepStone Group LP has disclosed TRDA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How StepStone Group LP's TRDA position evolved
StepStone Group LP first disclosed a stake in TRDA in Q3 2023 at 761,277 shares (US$12.0M). The position peaked in Q4 2024 at 761,277 shares, worth US$13.2M. Across 12 filings, StepStone Group LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 761,277 shares valued at US$5.6M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 761.28K | $12.03M | New |
| Q4 2023 | 761.28K | $11.49M | Hold |
| Q1 2024 | 761.28K | $10.79M | Hold |
| Q2 2024 | 761.28K | $10.85M | Hold |
| Q3 2024 | 761.28K | $12.17M | Hold |
| Q4 2024 | 761.28K | $13.16M | Hold |
| Q1 2025 | 761.28K | $6.88M | Hold |
| Q2 2025 | 761.28K | $5.12M | Hold |
| Q3 2025 | 761.28K | $4.42M | Hold |
| Q4 2025 | 761.28K | $7.83M | Hold |
| Q1 2026 | 761.28K | $9.61M | Hold |
| Q2 2026 | 761.28K | $5.60M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About TRDA and 13F data
TRDA (ENTRADA THERAPEUTICS INC) is a Health Care company. 36 other funds we track also report a position in TRDA — the largest reported positions include BAKER BROS. ADVISORS LP (US$37.3M), 5AM Venture Management, LLC (US$29.9M), Merck & Co., Inc. (US$12.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding TRDA
- BAKER BROS. ADVISORS LP 5.07M sh · $37.34M · Q2 2026
- 5AM Venture Management, LLC 4.06M sh · $29.85M · Q2 2026
- Merck & Co., Inc. 1.74M sh · $12.80M · Q2 2026
- MPM BioImpact LLC 1.25M sh · $9.22M · Q2 2026
- TCG Crossover Management, LLC 1.06M sh · $7.80M · Q2 2026
- Lynx1 Capital Management LP 178.61K sh · $1.31M · Q2 2026
More on StepStone Group LP
FAQ
How long has StepStone Group LP held TRDA?
StepStone Group LP has disclosed TRDA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is StepStone Group LP's current position in TRDA?
As of Q2 2026, StepStone Group LP holds 761.28K shares of TRDA (ENTRADA THERAPEUTICS INC), valued at $5.60M, representing 0.26% of its reported portfolio and ranking #9.
Has StepStone Group LP been buying or selling TRDA?
In the latest 13F filing (Q2 2026), StepStone Group LP held unchanged its position in TRDA. The position peaked in Q4 2024 at 761.28K shares.
Which other funds hold TRDA?
Other major institutional holders of TRDA include BAKER BROS. ADVISORS LP, 5AM Venture Management, LLC, Merck & Co., Inc., among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.